NCT00989404已完成1 期
A Randomized, Placebo Controlled, 3-Way Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo 10mg Administered Twice Daily for 5 Days by a Rotahaler Compared to the Diskhaler in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Safety and Tolerability: AEs, Labs, Vitals
研究概览
简要总结
The purpose of this study is to compare the safety and tolerability of Zanamivir using a Rotahaler device presentation to placebo within the Rotahaler presentation and to the Diskhaler device.
详细描述
The purpose of this study is to compare the safety and tolerability of Zanamivir using a Rotahaler to placebo within the Rotahaler presentation and to the Diskhaler. Eighteen subjects will receive each of three treatments for 5 days in a 3-way crossover design.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •The subject is healthy as judged by a responsible physician with no clinically significant abnormality identified on a medical evaluation
- •Male and female volunteers from 18-55 years of age, inclusively, at the time of signing the informed consent.
- •A female subject is eligible to participate if she is of: Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea or Child-bearing potential and agrees to use one of the contraception methods listed in the protocol for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point.
- •Male subjects must agree to use one of the contraception methods listed in the protocol.
- •Nonsmokers defined as abstinence from cigarette smoking for the previous 12 months before enrollment into the study.
- •Body mass Index of 19-30 kg/m
- •FEV1 greater than or equal to 85 percent of the predicted and FEV1/FVC ratio greater than or equal to 0.7 at screening.
- •Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
排除标准
- •The subject has a positive pre-study urine drug/ alcohol screen.
- •Significant pulmonary disease, such as chronic obstructive pulmonary disease, asthma, or other pulmonary diseases that may affect the pulmonary disposition of study drug or pose a safety risk for oral inhaled study drug.
- •Subjects with symptoms of upper respiratory infections at study entry.
- •Subjects currently presenting with chronic upper or lower respiratory tract infection, allergic rhinitis, hay fever, or sinusitis.
- •Significant psychiatric disease, such as anxiety disorders or psychotic disorders.
- •A creatinine clearance less than 70mL/min
- •History of regular alcohol consumption within 6 months of the study as defined in the protocol
- •Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
- •The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer)
- •Exposure to more than four experimental medications within 12 months prior to the first dosing day.
- •Ingestion of alcohol, grapefruit juice or grapefruit products, caffeine-containing food or beverage with 48 hours prior to the first dose of study medication and continuing through study completion.
- •Subjects who have donated blood to the extent where participation in the study would result in excess of 500mL blood donated within a 56 day period.
- •History of sensitivity to any of the study medications, or components thereof (including lactose) or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation. In addition, if heparin is used during pharmacokinetic sampling, subjects with a history of sensitivity to heparin or heparin-induced thrombocytopenia should not be enrolled.
- •Those who, in the opinion of the investigator, have a risk of non-compliance with study procedures.
- •Lack of suitability for participation in this study, for any reason, in the opinion of the investigator.
- •Subjects who, after training, are unable to use the study related devices.
- •The subject's systolic blood pressure is outside the range of 90-140mmHg, or diastolic blood pressure is outside the range of 45-90mmHg or heart rate is outside the range of 50-100bpm for female subjects or 45-100 bpm for male subjects.
研究组 & 干预措施
Period
Experimental
10 mg BID Zanamivir or placebo for 5 days
干预措施: Zanamivir (Drug)
结局指标
主要结局
Safety and Tolerability: AEs, Labs, Vitals
时间窗: Nineteen days
次要结局
- Pharmacokinetic parameters per protocol(Five days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With InfluenzaInfluenza, HumanNCT01231620GlaxoSmithKline626
已完成
3 期
Efficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in ChinaInfluenza A Virus InfectionInfluenza B Virus InfectionNCT01459081Jiangsu Simcere Pharmaceutical Co., Ltd.298
已完成
3 期
Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)Hepatitis C, ChronicNCT01370642Merck Sharp & Dohme LLC294
已完成
1 期
Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With CobicistatHuman Immunodeficiency Virus Type 1 (HIV-1)NCT01837719Bristol-Myers Squibb64
已完成
3 期
Study of Lopinavir/ Ritonavir and Lamivudine Versus Standard Therapy in Naïve HIV-1 Infected Subjects.HIV InfectionNCT01237444Pedro Cahn417